ArticleScientific reports2025
HIV/AIDS and HBV co-infection with optimal control strategies and cost-effectiveness analyses using integer order model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Pathogenesis and seroprevalence of dengue virus in HIV-endemic regions: A global perspective.New microbes and new infections · 2025Article
- Optimal control of dengue hemorrhagic fever model by classifying sex in West Java Province, Indonesia.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) and HIV/AIDS co-infection is a common infectious disease that has been spreading through different nations in the world. The main objective of the study is to minimize the number of HBV and HIV co-infected individuals in the community and the cost incurred to the effort applied towards protection and treatment control strategies. In this study, a novel HBV and HIV/AIDS co-infection model has been formulated and analyzed to investigate the effects of protection and treatment control strategies on the spreading dynamics of the HBV and HIV/AIDS co-infection in the community. In the qualitative analyses we have computed all the models disease-free equilibrium points, all the models effective reproduction numbers and unique endemic equilibrium points, we have proved the two sub-models disease-free equilibrium points are locally as well as globally asymptotically stable whenever their associated effective reproduction numbers are less than one. In our understanding no one is formulated and analyzed the HBV and HIV/AIDS co-infection model with optimal control and cost-effective analyses so that we have formulated the associated optimal control problem and carried out the optimal control analysis on the HBV and HIV/AIDS co-infection model by implementing the Pontryagin's minimum principle. Numerical simulations with various combinations of the control efforts implemented are then carried out to investigate the impacts of protection and treatments to tackle the HBV and HIV/AIDS co-infection diseases spreading in the community. Finally, we also carried out cost-effectiveness analysis for the implemented control strategies. From the findings of the numerical simulations we observed that implementing all the proposed controlling strategies simultaneously has fundamental impact to minimize and control the HBV and HIV/AIDS co-infection spreading in the community but cost-effectiveness analysis proved that implemented strategy 4 (implemented the HIV protection and HBV treatment controls simultaneously) is the most cost-effective strategy as compared with all other implemented strategies and we recommend for the health stake holders and policy makers to implement this strategy to tackle the HBV and HIV/AIDS co-infection spreading problem in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.